Connect with us

Hi, what are you looking for?

Jewish Business News

Mergers & Acquisitions

Three Way Takeover Battle: Teva set to buy Allergan’s generics unit – WSJ

Teva will pay over $45 billion for the botox maker unit, report the “Wall Street Journal.”

Teva CEO Erez Vigodman

Teva likely mean the end of Teva’s pursuit of another

Teva Pharmaceutical Industries Ltd. likely mean the end of pursuit of Mylan acquisition. The Israeli world’s biggest generic pharmaceutical maker is set to buy the generics unit of Allergan plc, in a deal worth $45 billion, the “Wall Street Journal” reports.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Sources familiar with the matter told WSJ that the deal could be announced on Monday.

In 2014, Allergan was the world’s third-largest seller of generic drugs after Teva and Novartis AG with $6.6 billion in sales, according to EvaluatePharma.

Teva is under pressure to consolidate its position in the market with a major acquisition because its top selling product for multiple-sclerosis treatment, Copaxone, started facing lower-priced competition in the U.S. last month due to its patent rights expired .

In April, Teva has been pursuing a hostile takeover bid for Mylan N.V. for more than $40 billion. Last week Mylan invoked a “poison pill” to avert the takeover, when the Dutch fund Stichting exercised its call option to temporarily takeover Mylan and protect it from being bought.

If the Allergan unit is spun off and merged with Teva, then Mylan’s $35 billion takeover bid for Perrigo Company could go ahead, as planned.


Bill Ackman

February 12th, 2015

One thing Allergan CEO David Pyott enjoyed doing was

running his company. When activist investor Bill Ackman

of Pershing Square decided to have Valeant Pharmaceuticals

try to swallow up the Botox maker in a hostile More…

Herbalife Plunges As Ackman Vows To Unveil Enron-Like Fraud

–   Hedge fund mogul William Ackman told investors they

could see a $6 billion payday when he closes the chapter on

Allergan Inc., his firm’s biggest bet of 2014. One week after

Allergan agreed to sell More…

Valeant chief executive Michael Pearson

The seven-month battle over American Botox haven pharmaceutical

company Allergan is over, after it accepted a friendly takeover bid

from Irish integrated specialty pharmaceutical Actavis. The Actavis

offer of combined More…

Bill Ackman 640x360

After an intense and acrimonious months long battle for a hostile takeover

of Allergan, Bill Ackman, who owns a 9.7% stake in the company, finally gave

up his battle to convene a special shareholders’ meeting More…

William BILL Ackman,   founder and CEO of hedge fund Pershing Square Capital Management,   speaks to audience about Herbalife company  in New York

– Activist investor William “Bill” Ackman said on Tuesday he supports

the $66 billion deal in which Actavis PLC will buy Allergan Inc and will

withdraw his request for an Allergan special shareholder More…

bill-ackman GETTY

– Botox maker Allergan Inc on Monday accepted a $66 billion

takeover bid from Actavis Plc, ending a seven-month hostile pursuit

by activist investor William (Bill) Ackman and Valeant Pharmaceuticals

International More…

Jim Cramer

Salix Pharmaceuticals was considered as a potential buy by Allergan to

ward off a hostile takeover by Valeant Pharmaceuticals and activist investor

Bill Ackman. Jim Cramer pointed out on CNBC that it is fortunate More…

Herbalife Plunges As Ackman Vows To Unveil Enron-Like Fraud

–   While federal judge David Carter said Allergan had raised ” serious questions”

about the legal implication of Bill Ackman’s Pershing Square and Valeant’s $53 billion

takeover bid,  More…

Bill Ackman facebook

In the ongoing hostile pursuit to take over Allergan, major shareholderin the

company, Bill Ackman and Valeant just don’t seem ready to quit, even though

the company has been doing quite well, thank you,  More…

Bill Ackman 640x360

It is no secret that Allergan has been in a war against Valeant Pharmaceuticals

and activist investor Bill Ackman, who owns a stake in Allergan, to avoid being

taken over by Valeant in what it sees as an offer More…



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.